Hong Kong Paper and Forestry Products Stock News

SEHK:9926
SEHK:9926Biotechs

Akeso (SEHK:9926) FY 2025 Loss Deepens Despite 2H Revenue Growth Challenging Bullish Narratives

Akeso (SEHK:9926) has reported FY 2025 results with second half revenue of C¥1.6b and a basic EPS loss of C¥0.60, while trailing 12 month revenue reached C¥3.1b against a net loss of C¥1.1b. The business has seen revenue move from C¥1.1b in 2H 2024 to C¥1.6b in 2H 2025, with basic EPS shifting from a loss of C¥0.32 to a loss of C¥0.60 over the same period, as investors weigh growth in the top line against persistent losses. Overall, the latest numbers point to expanding operations but...
SEHK:1357
SEHK:1357Interactive Media and Services

Meitu (SEHK:1357) Net Margin Jump To 25.4% Tests Bullish AI Earnings Narrative

Meitu (SEHK:1357) has just posted its FY 2025 first half scorecard, with revenue of CN¥1.8b and basic EPS of CN¥0.09, against a backdrop of trailing twelve month revenue of CN¥3.5b and EPS of CN¥0.20 that coincides with earnings growth of 97.9% over the past year. The company has seen revenue move from CN¥1.6b and EPS of CN¥0.07 in 1H 2024 to CN¥1.8b and EPS of CN¥0.09 in 1H 2025, while trailing net profit margin sits at 25.4% versus 14.9% a year earlier and sets up a margin story that...
SEHK:1211
SEHK:1211Auto

Assessing BYD (SEHK:1211) Valuation After Recent Share Price Strength And Long Term Returns

BYD stock overview BYD (SEHK:1211) has drawn fresh attention after recent share price moves, with the stock up over the past week, month and past 3 months, prompting investors to reassess its current valuation. See our latest analysis for BYD. At around HK$106.5, recent gains, including a 3.70% 1 day and 7.85% 30 day share price return, contrast with a 1 year total shareholder return of around a 20.59% decline. However, 3 and 5 year total shareholder returns of 43.41% and 85.91% suggest...
SEHK:2659
SEHK:2659Biotechs

Shanghai Bao Pharmaceuticals (SEHK:2659) Revenue Surges 7x While Losses Challenge Bullish Narratives

Shanghai Bao Pharmaceuticals (SEHK:2659) has reported its FY 2025 first half with revenue of C¥42.0 million and a basic EPS loss of C¥3.18, while trailing twelve month figures show revenue of C¥49.2 million against a net loss of C¥395.3 million and EPS of C¥1.36 in the red. Over the past few reporting halves, revenue has moved from C¥1.49 million in 2024 H1 to C¥4.67 million in 2024 H2 and then to C¥42.0 million in 2025 H1, as EPS stayed firmly negative across all periods. This sets up a...
SEHK:1090
SEHK:1090Metals and Mining

Da Ming International Holdings (SEHK:1090) Returns To Profit In 1H 2025 Challenging Bearish Narratives

Da Ming International Holdings (SEHK:1090) has opened FY 2025 with first half revenue of CNY 21.2b and basic EPS of CNY 0.01, while the trailing twelve months still reflect a loss with basic EPS at CNY 0.03 on revenue of CNY 44.2b and net loss excluding extra items of CNY 35.6m. Over the past three reported half year periods, revenue has moved from CNY 22.8b in 1H 2024 to CNY 23.7b in 2H 2024 and then to CNY 21.2b in 1H 2025, with net income excluding extra items shifting from CNY 4.4m to a...